Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group.

Nachury, Maria; Bouhnik, Yoram; Serrero, Melanie; Filippi, Jerome; Roblin, Xavier; Kirchgesner, Julien; Bouguen, Guillaume; Franchimont, Denis; Savoye, Guillaume; Buisson, Anthony; Louis, Edouard; Nancey, Stephane; Abitbol, Vered; Reimund, Jean-Marie; DeWit, Olivier; Vuitton, Lucine; Matthieu, Nicolas; Peyrin-Biroulet, Laurent; Gilletta, Cyrielle; Tadbiri, Sara; Allez, Matthieu; Viennot, Stephanie; Bourreille, Arnaud; Laharie, David; Amiot, Aurelien

doi:10.1016/j.dld.2020.10.020

Article (Scientific journals)

Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group.

Nachury, Maria; Bouhnik, Yoram; Serrero, Melanie et al.

2021 • In Digestive and Liver Disease

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/254801

DOI
10.1016/j.dld.2020.10.020

PubMed
33187920

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Patients real-world experience with OBD...GETAID Group_DigLivDis_corr proef in press.pdf

Author postprint (655 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Crohn's disease; Inflammatory bowel disease; Patients experience; Ulcerative colitis

Abstract :

[en] BACKGROUND: Patients' experience with healthcare professionals could influence their clinical outcomes. AIMS: To assess inflammatory bowel disease (IBD) patients' experience with their disease, their treatment and their relationship with their physician. METHODS: A one-week cross-sectional study was conducted in 42 IBD centres. 2011 consecutive outpatients with IBD completed an anonymous self-report questionnaire assessing their experience with and knowledge of IBD. RESULTS: A quantitative assessment of the doctor-patient relationship revealed that patients' knowledge of IBD and IBD treatment ranged from 7.4 to 8.3 out of 10. In addition to IBD physicians, other sources of information about IBD and current treatment mainly included the internet (80% and 63%, respectively) and general practitioners (61% and 54%). Knowledge about education programmes (28%) was poor, resulting in a lack of willingness to further use these resources (25%). Concerns about IBD treatment were raised in 76% of patients, mostly related to the fear of adverse events (47%) and a lack of efficacy (33%). The need of alternative healthcare professionals was reported by 89% of the sample. CONCLUSION: In a large cohort of patients, we highlighted gaps in the management of patients with IBD regarding the need for higher-quality information and the implementation of alternative healthcare professionals.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Nachury, Maria

Bouhnik, Yoram

Serrero, Melanie

Filippi, Jerome

Roblin, Xavier

Kirchgesner, Julien

Bouguen, Guillaume

Franchimont, Denis

Savoye, Guillaume

Buisson, Anthony

More authors (15 more)

Other collaborator :

Reenaers, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

Language :

English

Title :

Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group.

Publication date :

2021

Journal title :

Digestive and Liver Disease

ISSN :

1590-8658

eISSN :

1878-3562

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://doi.org/10.1016/j.dld.2020.10.020

Commentary :

Available on ORBi :

since 06 January 2021

Statistics

Number of views

137 (3 by ULiège)

Number of downloads

188 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Torres, J., Mehandru, S., Colombel, J.-F., Peyrin-Biroulet, L., Crohn's disease. Lancet 389 (2017), 1741–1755, 10.1016/S0140-6736(16)31711-1.
Ungaro, R., Mehandru, S., Allen, P.B., Peyrin-Biroulet, L., Colombel, J.-F., Ulcerative colitis. Lancet 389 (2017), 1756–1770, 10.1016/S0140-6736(16)32126-2.
Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., Reinisch, W., Bemelman, W., Bryant, R.V., et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338, 10.1038/ajg.2015.233.
Marín-Jiménez, I., Casellas, F., Cortés, X., García-Sepulcre, M.F., Juliá, B., Cea-Calvo, L., et al. The experience of inflammatory bowel disease patients with healthcare: a survey with the IEXPAC instrument. Medicine (Baltimore), 98, 2019, e15044, 10.1097/MD.0000000000015044.
Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J.O., et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11 (2017), 3–25, 10.1093/ecco-jcc/jjw168.
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11 (2017), 649–670, 10.1093/ecco-jcc/jjx008.
Rouillon, C., Peyrin-Biroulet, L., Bouhnik, Y., Louis, E., Beaugerie, L., Etat des lieux sur les MICI en France: enquete national du GETAID. Hépato-Gastro Oncol Digest 26 (2019), 167–176.
Koliani-Pace, J.L., Haron, A.M., Zisman-Ilani, Y., Thompson, K.D., Siegel, C.A., Patients’ perceive biologics to be riskier and more dreadful than other IBD medications. Inflamm Bowel Dis, 2019, 10.1093/ibd/izz121.
Petitdidier, N., Tannoury, J., de'Angelis, N., Gagniere, C., Hulin, A., Rotkopf, H., et al. Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Dig Liver Dis 51 (2019), 1652–1660, 10.1016/j.dld.2019.08.020.
Lofland, J.H., Johnson, P.T., Ingham, M.P., Rosemas, S.C., White, J.C., Ellis, L., Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adher 11 (2017), 947–958, 10.2147/PPA.S133222.
Stacey, D., Légaré, F., Lewis, K., Barry, M.J., Bennett, C.L., Eden, K.B., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev, 4, 2017, CD001431, 10.1002/14651858.CD001431.pub5.
Singh, S., Picardo, S., Seow, S.H., Management of inflammatory bowel diseases in special population: obese, old, or obstetric. Clin Gastroenterol Hepatol 18:6 (2020), 1367–1380 Clin Gastroenterol Hepatol 2020;18:1367–80.
Komaki, Y., Yamada, A., Komaki, F., Kudaravalli, P., Micic, D., Ido, A., et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun 79 (2017), 4–16, 10.1016/j.jaut.2017.02.003.
Edwards, C.J., Hercogová, J., Albrand, H., Amiot, A., Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 19 (2019), 1001–1014, 10.1080/14712598.2019.1610381.
Baumgart, D.C., Misery, L., Naeyaert, S., Taylor, P.C., Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?. Front Pharmacol, 10, 2019, 279, 10.3389/fphar.2019.00279.
Pentek, M., Zrubka, Z., Gulacsi, L., The economic impact of biosimilars on chronic immune-mediated inflammatory diseases. Curr Pharm Des 23 (2017), 6770–6778, 10.2174/1381612824666171129193708.
Peyrin-Biroulet, L., Lönnfors, S., Roblin, X., Danese, S., Avedano, L., Patient perspectives on biosimilars: a survey by the European federation of crohn's and ulcerative colitis associations. J Crohns Colitis 11 (2017), 128–133, 10.1093/ecco-jcc/jjw138.
Peyrin-Biroulet, L., Lönnfors, S., Avedano, L., Danese, S., Changes in inflammatory bowel disease patients’ perspectives on biosimilars: a follow-up survey. United Eur Gastroenterol J 7 (2019), 1345–1352, 10.1177/2050640619883704.
Selinger, C.P., Carbery, I., Warren, V., Rehman, A.F., Williams, C.J., Mumtaz, S., et al. The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. Aliment Pharmacol Ther 45 (2017), 63–74, 10.1111/apt.13831.
Selinger, C.P., Lal, S., Eaden, J., Jones, D.B., Katelaris, P., Chapman, G., et al. Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease. J Crohns Colitis 7 (2013), e214–e218, 10.1016/j.crohns.2012.09.014.
Cima, R.R., Anderson, K.J., Larson, D.W., Dozois, E.J., Hassan, I., Sandborn, W.J., et al. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis 13 (2007), 1266–1270, 10.1002/ibd.20198.
Complementary, alternative, or integrative health: what's in a name? 2018.
Hilsden, R.J., Verhoef, M.J., Rasmussen, H., Porcino, A., DeBruyn, J.C.C., Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 17 (2011), 655–662, 10.1002/ibd.21360.
Torres, J., Ellul, P., Langhorst, J., Mikocka-Walus, A., Barreiro-de Acosta, M., Basnayake, C., et al. European crohn's and colitis organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis, 13, 2019, 673, 10.1093/ecco-jcc/jjz051 –685e.
Abitbol, V., Lahmek, P., Buisson, A., Olympie, A., Poupardin, C., Chaussade, S., et al. Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey. Eur J Gastroenterol Hepatol 26 (2014), 288–294, 10.1097/MEG.0000000000000040.